Nebula Genomics: Whole Genome Sequencing, Data Ownership, and the Case for Reading Every Base Pair

While most consumer genetic tests read a fraction of your genome, Nebula sequences all 3.2 billion base pairs and lets you keep the data. Is whole genome sequencing ready for the health-conscious consumer?

Presented By Our Partners

The human genome contains approximately 3.2 billion base pairs of DNA. When a consumer takes a standard genotyping test from 23andMe or AncestryDNA, the lab reads roughly 730,000 of those positions, about 0.02% of the total genome. The remaining 99.98% goes unexamined. For ancestry analysis and a handful of well-characterized health variants, this approach is sufficient. But for anyone who wants the most complete picture of their genetic blueprint, including rare variants, structural rearrangements, and novel mutations that genotyping arrays simply cannot detect, the math is unsatisfying. Nebula Genomics was founded in 2018 by George Church, a professor of genetics at Harvard Medical School and one of the architects of the Human Genome Project, with a thesis built around two principles: that consumers deserve access to their complete genome, and that they should own the data it produces. The company offers whole genome sequencing (WGS) at 30x or 100x depth, meaning every base pair in the genome is read an average of 30 or 100 times for accuracy verification. In a market dominated by SNP arrays that sample a curated subset of variants, Nebula occupies a fundamentally different tier of genomic information.

What Is Nebula Genomics WGS?

Nebula Genomics offers at-home whole genome sequencing through a saliva collection kit. Users choose between 30x WGS ($299) or 100x WGS (up to $999), where the “x” denotes the average number of times each base pair is read during the sequencing process. Higher depth means greater accuracy, particularly for detecting rare variants and variants in regions of the genome that are difficult to sequence. The sample is processed in a CLIA-certified and CAP-accredited laboratory.

Results are delivered through Nebula’s online platform and include ancestry analysis, health trait reports, and access to an expanding library of genomic research reports that interpret newly published studies in the context of the user’s own genome. Critically, Nebula provides the complete raw genome data file (in standard FASTQ, BAM, or VCF formats) for download, giving users full ownership and portability of their genomic information. This raw data can be analyzed by third-party bioinformatics tools, shared with healthcare providers, or stored privately for future analysis as genomic science advances.

Nebula’s privacy architecture is a deliberate departure from the standard DTC model. The company uses privacy-preserving technology and does not sell user data to pharmaceutical companies or third parties. Users can opt into research participation and data sharing on their own terms, reversing the model that 23andMe and AncestryDNA have used to monetize aggregated genetic data.

The Science Behind It: Why Depth and Completeness Matter

The distinction between SNP genotyping and whole genome sequencing is not merely technical; it is the difference between reading a summary and reading the entire book. SNP arrays test preselected positions, which means they can only detect variants that were already known and deemed important when the array was designed. Novel variants, rare mutations, copy number variations, insertions, deletions, and structural rearrangements are invisible to genotyping arrays. WGS reads everything, enabling the detection of both known and previously uncharacterized variants.

This distinction has direct clinical implications. A 2022 systematic review published in Frontiers in Genetics by Shen et al. found that 1% to 3% of the general population carries a clinically actionable genetic variant. Many of these variants are rare enough that they would not appear on a standard SNP array. Clinical genetic testing for hereditary cancer, for example, uses sequencing (not genotyping) to examine the full coding region of genes like BRCA1, BRCA2, MLH1, and MSH2, because pathogenic mutations can occur at nearly any position within these genes. The three BRCA variants that 23andMe tests for represent a tiny fraction of the over 1,000 known pathogenic BRCA mutations.

A 2022 review published in the Journal of Internal Medicine by Li et al. explored how epigenetic aging research is moving beyond chronological age prediction toward understanding the mechanisms of aging and informing clinical practice. While this work focuses on DNA methylation rather than genomic sequence, it illustrates the trajectory of molecular diagnostics: comprehensive measurement is increasingly preferred over selective screening. WGS positions the user to benefit from future discoveries, because the data captured today can be reanalyzed against new findings for decades, something a SNP array cannot offer since it only captures the variants it was designed to test.

The 30x sequencing depth is the current standard for clinical-grade WGS. At this depth, the probability of accurately calling a variant at any given position exceeds 99%. The 100x option increases confidence further, particularly in genomic regions with high GC content or repetitive sequences that are more difficult to resolve. For most consumer applications, 30x provides sufficient accuracy; 100x is more relevant for users with specific clinical questions or those planning to use the data in a medical context. That is the science. Here is how Nebula applies it.

What Nebula Genomics Does Well

Nebula’s fundamental advantage is completeness. By sequencing the entire genome rather than sampling a subset of known variants, it provides orders of magnitude more genetic information than any genotyping-based competitor. This completeness is not just academic; it means the data retains value as genomic science progresses. When researchers identify a new variant associated with disease risk in 2028, Nebula users can check their existing genome file for that variant. 23andMe and AncestryDNA users cannot, unless the variant happens to be one of the positions already on their array.

Data ownership and portability set Nebula apart from every major competitor. The complete genome file (typically 50 to 100 gigabytes at 30x depth) belongs to the user, is downloadable in standard bioinformatics formats, and can be analyzed with any compatible tools. This is a meaningful philosophical and practical distinction. Users are not locked into Nebula’s interpretation layer; they can take their data to genetic counselors, research institutions, or bioinformatics platforms for independent analysis.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The privacy-first model addresses one of the most significant concerns in consumer genomics. Following 23andMe’s 2023 data breach and ongoing debates about genetic data monetization, Nebula’s approach of not selling user data to third parties and offering privacy-preserving research participation resonates with users who understand the permanent, irreplaceable nature of genetic information. The company’s founding by George Church, a towering figure in genomics, lends scientific credibility that few DTC platforms can match.

Pricing, Access, and Practical Realities

Nebula Genomics 30x WGS is priced at approximately $299, making it competitive with 23andMe Health + Ancestry ($229) while delivering vastly more genetic data. The 100x WGS option ranges up to $999 for maximum sequencing depth. No subscription is required, and results are accessible through Nebula’s platform indefinitely. Raw data downloads are available at no additional cost.

No physician order is required. The test is available directly to consumers, though Nebula encourages users to consult healthcare providers when interpreting results with potential medical significance. Results are typically delivered within 8 to 12 weeks, somewhat longer than genotyping services due to the computational demands of sequencing and variant calling.

Nebula Genomics is not currently FDA authorized for specific health claims. The health reports provided through the platform are informational, not diagnostic, and should not be used as the sole basis for medical decisions. The test is not typically HSA or FSA eligible, though users should check with individual plan administrators. The CLIA certification and CAP accreditation of the sequencing laboratory provide quality assurance standards consistent with clinical testing.

Who Nebula Genomics Is Best For

Nebula is ideal for biohackers and quantified self enthusiasts who want the most comprehensive genetic dataset possible and the technical literacy to use it. It suits users who prioritize data ownership and privacy, particularly those who are uncomfortable with the data monetization practices of larger DTC platforms. Researchers and healthcare professionals who want to explore their own genome or recommend comprehensive testing to patients will value the clinical-grade sequencing depth and standard data formats. Forward-thinking health consumers who understand that genomic science is rapidly evolving will appreciate that WGS data retains its value for decades of future reanalysis.

Those who should choose alternatives include consumers who want simple, curated health reports without needing to interpret raw data, as 23andMe provides a more user-friendly health reporting experience. Users whose primary interest is ancestry and genealogy will get more value from AncestryDNA’s 20+ million person database, since Nebula’s smaller user base limits relative matching. Anyone seeking specific, FDA-authorized health screening (BRCA, pharmacogenomics) should note that Nebula’s reports are informational, not FDA-reviewed, and clinical-grade targeted testing from Color Health or Myriad Genetics may be more appropriate for medical decision-making. Budget-conscious users who want basic health genetics should consider 23andMe’s lower entry point.

How Nebula Genomics Compares

23andMe Health + Ancestry ($229) uses SNP genotyping to read approximately 730,000 variants with FDA-authorized health reports. Nebula 30x WGS ($299) reads all 3.2 billion base pairs with informational (non-FDA) health reports. The data quantity difference is several orders of magnitude: Nebula provides roughly 4,000 times more genetic data. However, 23andMe’s health reports have undergone FDA review for specific variants, providing a level of regulatory validation that Nebula’s reports lack.

AncestryDNA ($99) is less expensive but provides only ancestry analysis with no health reports and reads fewer genetic positions. Color Health ($249) offers clinical-grade, FDA-authorized testing focused on hereditary cancer and cardiac risk with genetic counseling included, making it the better choice for specific medical screening needs. Among WGS providers, Dante Labs and Veritas Genetics offer competing whole genome sequencing services at various price points, but Nebula’s combination of Harvard-affiliated science, privacy-first architecture, and raw data portability distinguishes it in this space.

Limitations and Open Questions

The most significant limitation for average consumers is interpretability. A whole genome dataset contains millions of variants, the vast majority of which have unknown significance. Without advanced bioinformatics knowledge or genetic counseling support, the sheer volume of data can be overwhelming rather than empowering. Nebula’s reporting platform translates some of this data into accessible health and trait reports, but the depth of interpretation does not yet match the depth of data collection.

The absence of FDA authorization for health reports means that any actionable findings should be confirmed through clinical-grade testing before making medical decisions. Nebula explicitly recommends this, but the distinction between informational and diagnostic results is not always clear to consumers. The longer turnaround time (8 to 12 weeks) and larger data files may frustrate users accustomed to the faster, more streamlined experience of genotyping services.

Nebula’s smaller user base compared to 23andMe and AncestryDNA limits its utility for relative matching and ancestry analysis. Users primarily interested in finding genetic relatives will find the larger databases more productive. The company is smaller and more recently founded than its major competitors, which introduces questions about long-term business viability and data custodianship, an important consideration when the product is your permanent genetic blueprint.

What This Means for Your Health

Whole genome sequencing represents the most comprehensive snapshot of inherited genetic risk currently available to consumers. Within Healthcare Discovery‘s longevity framework, understanding your genome is one layer of a multi-layer health optimization strategy. Your inherited DNA sequence tells you about the predispositions you carry for the Four Shadows: cardiovascular disease, cancer, neurodegenerative disease, and metabolic dysfunction. But predisposition is not destiny. The Five Pillars of Nutrition, Sleep, Movement, Breathwork, and Mindset represent the modifiable factors that determine whether genetic risks manifest as disease.

Nebula Genomics is the most forward-looking choice in consumer genetics because WGS data appreciates in value over time. Every year, researchers identify new variants associated with disease risk, drug response, and biological function. A genome sequenced today can be reanalyzed against these discoveries for decades. A SNP array, by contrast, is fixed at the moment of manufacture, unable to reveal what it was not designed to look for.

The practical recommendation: if you are going to invest in genetic testing and want the most complete, portable, and future-proof dataset, Nebula Genomics at 30x depth offers the best combination of comprehensiveness and value. Pair it with clinical follow-up for any concerning findings, an epigenetic age test (TruDiagnostic or Elysium) for biological age assessment, and the foundational health practices that the evidence shows matter most for longevity. Your genome is the blueprint. How you maintain the structure it describes is where the real health optimization happens.

Frequently Asked Questions

What is the difference between 30x and 100x whole genome sequencing?
The “x” refers to average sequencing depth, or how many times each base pair in the genome is read. At 30x, each position is read an average of 30 times, providing over 99% accuracy for variant detection. At 100x, accuracy increases further, particularly for variants in difficult-to-sequence genomic regions. For most consumer applications, 30x ($299) is sufficient. The 100x option (up to $999) is more relevant for users with specific clinical questions or those planning to use the data in a medical context.

Can I share my Nebula Genomics data with my doctor?
Yes. Nebula provides complete raw genome files in standard bioinformatics formats (FASTQ, BAM, VCF) that can be shared with healthcare providers, genetic counselors, or research institutions. This data portability is a key differentiator. However, because Nebula’s reports are informational, not diagnostic, your healthcare provider may want to confirm any clinically significant findings through clinical-grade testing before making treatment decisions.

How does Nebula Genomics protect my genetic data?
Nebula uses a privacy-first architecture and does not sell user data to pharmaceutical companies or third parties. Users retain ownership of their genome files and can opt into research participation on their own terms. This contrasts with some competitors whose business models involve monetizing aggregated genetic data. Users can download and delete their data from the platform at any time.

Is Nebula Genomics better than 23andMe for health information?
Nebula provides vastly more genetic data (all 3.2 billion base pairs vs. approximately 730,000 SNPs) but its health reports are informational, not FDA-authorized. 23andMe offers FDA-authorized reports for specific variants (BRCA1/2, pharmacogenomics, carrier status) that have undergone regulatory review. For curated, FDA-reviewed health screening, 23andMe is currently stronger. For comprehensive genomic data with long-term reanalysis value, Nebula provides significantly more information.

How long does Nebula Genomics take to deliver results?
Results are typically delivered within 8 to 12 weeks after the laboratory receives the saliva sample. This is longer than genotyping services like 23andMe (3 to 5 weeks) and AncestryDNA (6 to 8 weeks) because whole genome sequencing generates vastly more data and requires more computational processing for variant calling and quality control. The raw genome data file at 30x depth is approximately 50 to 100 gigabytes.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.